Literature DB >> 8659116

Gain of Sp1 sites and loss of repressor sequences associated with a young, transcriptionally active subset of HERV-H endogenous long terminal repeats.

D T Nelson1, N L Goodchild, D L Mager.   

Abstract

HERV-H sequences comprise a large family of human endogenous retrovirus-like elements. Previous DNA sequence comparisons of HERV-H long terminal repeats (LTRs) have led to their classification into three subtypes, Types I, Ia, and II. Type Ia appears to have been generated by recombination between Type I and Type II LTRs. These subtypes differ in evolutionary age and transcriptional activity with Type Ia LTRs being younger in evolutionary terms and possessing stronger promoter function than the other two subtypes. In this study, possible mechanisms responsible for the functional difference between LTRs have been explored. Types I and II LTRs each contain different sets of repeated segments in their U3 regions which are disrupted in Type Ia LTRs. Using reporter gene assays, we have shown that both types of repeated segments can suppress activity of the human beta-globin gene promoter when cloned at a distant site. Both sets of repeats also repress promoter activity of a Type Ia LTR when directly inserted within its U3 region. In addition, using deletion constructs, we have localized two positive regulatory segments within the Type Ia LTR, both of which contain a potential binding site for the transcription factor Sp1. Gel mobility shift assays demonstrated that fragments containing these sites do bind Sp1. Although Type I LTRs are generally similar to Type Ia LTRs in the regions surrounding the Sp1 sites, there are sequence differences within the sites. Gel-shift analysis revealed no or much reduced Sp1 binding of Type I LTR fragments containing these sites. Thus, it appears that the loss of repeated suppresser elements and the acquisition of Sp1-binding sites have both contributed to the relatively strong transcriptional activity of the Type Ia LTRs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659116     DOI: 10.1006/viro.1996.0303

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray.

Authors:  Wolfgang Seifarth; Oliver Frank; Udo Zeilfelder; Birgit Spiess; Alex D Greenwood; Rüdiger Hehlmann; Christine Leib-Mösch
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription.

Authors:  Chunhong Yu; Xiaoyun Lei; Fang Chen; Song Mao; Lu Lv; Honglu Liu; Xueying Hu; Runhan Wang; Licong Shen; Na Zhang; Yang Meng; Yunfan Shen; Jiale Chen; Pishun Li; Shi Huang; Changwei Lin; Zhuohua Zhang; Kai Yuan
Journal:  Nat Commun       Date:  2022-06-17       Impact factor: 17.694

3.  Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker.

Authors:  Yun-Ji Kim; Jae-Won Huh; Dae-Soo Kim; Min-In Bae; Ja-Rang Lee; Hong-Seok Ha; Kung Ahn; Tae-Oh Kim; Geun-Am Song; Heui-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-10       Impact factor: 4.553

4.  Presence of dUTPase in the various human endogenous retrovirus K (HERV-K) families.

Authors:  Jens Mayer; Eckart U Meese
Journal:  J Mol Evol       Date:  2003-12       Impact factor: 2.395

5.  Human endogenous retroviral long terminal repeat sequences as cell type-specific promoters in retroviral vectors.

Authors:  Ulrike Schön; Olivia Diem; Laura Leitner; Walter H Günzburg; Dixie L Mager; Brian Salmons; Christine Leib-Mösch
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

6.  Repression of Human T-lymphotropic virus type 1 Long Terminal Repeat sense transcription by Sp1 recruitment to novel Sp1 binding sites.

Authors:  Sylvain Fauquenoy; Gwenaëlle Robette; Anna Kula; Caroline Vanhulle; Sophie Bouchat; Nadège Delacourt; Anthony Rodari; Céline Marban; Christian Schwartz; Arsène Burny; Olivier Rohr; Benoit Van Driessche; Carine Van Lint
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.